Takeda Pharmaceutical Company Ltd
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
Takepron Intravenous 30 mg Specified Drug-use Survey [Acute Stress Ulcer and Acute Gastric Mucosal Lesions]
Completed
- Conditions
- Acute Stress Ulcer and Acute Gastric Mucosal Lesions
- Interventions
- First Posted Date
- 2014-06-23
- Last Posted Date
- 2016-03-08
- Lead Sponsor
- Takeda
- Target Recruit Count
- 63
- Registration Number
- NCT02170207
Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairment
- First Posted Date
- 2014-06-23
- Last Posted Date
- 2016-01-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 12
- Registration Number
- NCT02170220
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey "Long-term Use Survey in Prostate Cancer Patients (96 Weeks)"
- First Posted Date
- 2014-06-19
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Takeda
- Target Recruit Count
- 11288
- Registration Number
- NCT02167893
Blopress Tablets Specified Drug-use Survey "Hypertension: Survey on Patients With Metabolic Syndrome"
- First Posted Date
- 2014-06-18
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 14151
- Registration Number
- NCT02166697
Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder.
Phase 1
Terminated
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- Drug: TAK-137Drug: TAK-137 Placebo
- First Posted Date
- 2014-06-16
- Last Posted Date
- 2016-07-11
- Lead Sponsor
- Takeda
- Target Recruit Count
- 47
- Registration Number
- NCT02163915
Bioavailability and Pharmacokinetics of Vedolizumab in Healthy Participants Following Single Subcutaneous Administration
- First Posted Date
- 2014-06-13
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- Takeda
- Target Recruit Count
- 48
- Registration Number
- NCT02163421
Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett's Esophagus With Radiofrequency Ablation
Phase 2
Terminated
- Conditions
- Barrett's Esophagus
- Interventions
- First Posted Date
- 2014-06-13
- Last Posted Date
- 2017-05-11
- Lead Sponsor
- Takeda
- Target Recruit Count
- 6
- Registration Number
- NCT02162758
Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Strain/TO-336 Strain) Specified Drug-use Survey of Vaccinees After the Second Vaccination
Completed
- Conditions
- Measles/Rubella
- Interventions
- Drug: Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
- First Posted Date
- 2014-06-06
- Last Posted Date
- 2018-02-23
- Lead Sponsor
- Takeda
- Target Recruit Count
- 3331
- Registration Number
- NCT02158364
Leuprorelin Acetate SR 11.25 mg for Injection Specified Drug-use Survey "Long-term Use Survey on Premenopausal Breast Cancer Patients (96 Weeks)"
- First Posted Date
- 2014-06-03
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- Takeda
- Target Recruit Count
- 651
- Registration Number
- NCT02154139
Evaluation of the Safety and Efficacy of Long-term Use of Omega-3 Fatty Acid Ethyl Esters
- First Posted Date
- 2014-06-02
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- Takeda
- Target Recruit Count
- 3084
- Registration Number
- NCT02153073
© Copyright 2025. All Rights Reserved by MedPath